Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EF-022 in Advanced Solid Malignancies
NCT02052492Phase 1Completed
- Sponsor
- Efranat Ltd.
- Start
- May 2014
- Primary completion
- May 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of gcmaf in solid tumor (4 cohorts), sponsored by Efranat Ltd. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Adverse Events Grade 3-4 at 8 weeks. Started May 2014; status: completed.
02
Drugs
gcmaf
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02052492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052492.